Singapore’s Singapore Eye Research Institute (SERI) has cemented its position as a global leader in ophthalmology, achieving the #1 ranking among non-academic institutes and #2 overall globally, according to the latest ScholarGPS assessment. This isn’t simply an academic accolade; it signals a broader shift in medical research dominance towards the Asia-Pacific region and highlights Singapore’s strategic investment in becoming a biomedical hub. The ranking, based on five years of data through December 2025, reflects SERI’s increasing impact on both scientific understanding and, crucially, patient care.
- Global Recognition: SERI’s #1 ranking among non-academic ophthalmology institutes and #2 overall demonstrates its world-class research capabilities.
- Translational Success: The institute’s focus on translating research into tangible patient benefits – like reduced injection frequency for macular degeneration and treatments for myopia – is a key differentiator.
- Singapore’s Rising Profile: This achievement reinforces Singapore’s position as a leading center for medical innovation in the Asia-Pacific region.
SERI, established in 1997 as the national research institute for ophthalmic and vision research, has consistently pushed the boundaries of eye care. Its success is built on a foundation of strong collaboration with the Singapore National Eye Centre (SNEC) and a commitment to addressing the specific needs of Asian populations, who often experience higher rates of certain eye diseases. The institute’s rise parallels a global trend of increasing investment in preventative and personalized medicine, with ophthalmology benefiting from advancements in areas like artificial intelligence and gene therapy. The ScholarGPS ranking methodology, which considers research output, citation impact, and scholarly influence, provides a robust and independent validation of SERI’s contributions.
The impact of SERI’s work extends beyond publications and citations. The development and commercialization of treatments like Vabysmo (faricimab) – reducing injection frequency for diabetic eye diseases and age-related macular degeneration – and Myopine, a low-dose atropine eye drop for childhood myopia, demonstrate a clear pathway from lab to patient. Furthermore, innovations like the EndoGlide corneal transplant device and the Polarisation-Sensitive Optical Coherence Tomography showcase SERI’s ability to create cutting-edge diagnostic and therapeutic tools. Perhaps most significantly, the development of SELENA+, an AI-powered screening tool for diabetic retinopathy, positions Singapore as a pioneer in leveraging artificial intelligence to address public health challenges.
The Forward Look
SERI’s success is likely to attract further investment and talent to Singapore, solidifying its position as a regional hub for ophthalmic research. We can anticipate increased collaboration between SERI and international institutions, particularly in areas like gene therapy and advanced imaging techniques. The institute’s continued focus on AI-driven diagnostics and personalized treatment plans will be crucial, especially as the global population ages and the prevalence of age-related eye diseases increases. A key area to watch is the expansion of SELENA+ and similar AI screening tools to other countries, potentially revolutionizing early detection and prevention of blindness on a global scale. Furthermore, the institute’s 188 patents suggest a robust pipeline of future innovations poised for commercialization, promising continued advancements in eye care for years to come. The challenge will be to maintain this momentum amidst increasing global competition and to ensure equitable access to these advancements for patients worldwide.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
